In light of the potential adverse effects of systemic AMD3100 treatment, which include thrombocytopenia observed in HIV-infected patients [43], the development of topical anti-SDF-1/CXCR4 therapies might represent a more promising avenue for inhibiting chronic inflammatory skin disorders such as psoriasis. The gene discussed is CXCR4; the disease is Thrombocytopenia.